Subst. for form 1449/PTO SUPPLEMENTAL								Complete if Known Application Number 10/735,863						
			CLOSURE		EMEN	TBY	Filing Date			2003-12-15				
			R 37 CFR 1 necessary)	1.97(1)				First Named Inventor			Lee Bre			
							Art Unit				164			
June 24, 2	2009							Examiner Name		Schv		, Ronald	I B.	
Sheet		1		of		3	Docket Number				079259			
,				l		U.S	. P	PATENTS	L					
EXAMINE	ER'S	CITE	Patent	t Number	T	Publication Da	ite	Name of Patentee	or L	Applicant I			Lines, Where	
INITIAI	.S	NO.	i atent Number			YYYY-MM-DD							s or Relevant	
				J	J.S. PA	TENT APPI	LIC	CATION PUBLICAT	IONS	5			A TO I TAKEN TO SERVICE METERS	
EXAMINER'S INITIALS		CITE Publi NO.		Publication Number		Publication Date YYYY-MM-DD		Name of Patentee of Cited Do	Relevant		ant Passage	Columns, Lines, Where It Passages or Relevant Figures Appear		
						FOREIGN PA	ΑT	ENT DOCUMENTS						
					Publication Da YYY-MM-DD		Name of Patentee or Applicant of Cited Docum		Pages, Colum Where Rel Figures Ap	Relevant		anslation		
												Yes	No	
								277						
									_					
													<u> </u>	

Subst. for						Complete if Known					
SUPPLI				HDE STAT	EMENT BY	Application Number 10/735,863					
				FR 1.97(i)	CIVICIVIDI	Filing Date 2003-12-15					
(Use as n						First Named Inventor	Lee Brettman				
June 24,	2000					Art Unit	1644				
June 24,	2009					Examiner Name	Schwadron, Ronald B.				
Sheet		2		Of	3	Docket Number	079259-0237				
						or, Title, Date, Pertin					
EXAMIN INITIA		CITE NO.	(book, city and	magazine, jou d/or country w	ırnal, serial, symposium here published.	n, catalog, etc.), date, page	(when appropriate), title of the item (s), volume-issue number(s), publisher,				
		AV5	KOLA Drug l	, Ismail, et a Discovery, A	I., "Can the pharmadugust 2004, pp 711-	ceutical industry reduce 715, Vol. 3	attrition rates?", Nature Reviews,				
		AW5	MA, P Vol. 1	hilip, et al.,	"Value of novelty?", I	Nature Reviews, Drug D	iscovery, August 2002, pp 571-572,				
		AX5			., et al., "Treatment J. Med., 352:2499-2	t of Ulcerative Colitis with a Humanized Antibody to the $\alpha_4\beta_7$ 2507 (2005).					
		AY5					n MLN0002, a humanized antibody Dec;6(12):1370-7 (Abstract only)				
)))				
EXAMINER						<u> </u>	DATE CONSIDERED				
			L/V				-··				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered Include copy of this form with next communication to applicant

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

	form 1449/PTO			Complete if Known			
	EMENTAL	UDE CTAT	EMENT DV	Application Number 10/735,863			
	IATION DISCLOS ANT UNDER 37 C		ENENIBY	Filing Date	2003-12-15 Lee Brettman		
	any sheets as neces			First Named Inventor			
				Art Unit	1644		
June 24, 2	2009			Examiner Name	Schwadron, Ronald B.		
	3		3	Docket Number	079259-00237		

CERTIFICATION STATEMENT

	Please	See	37	CFR	1.97	and	1.98	to	make	the	app	ropriate	selection	(s)
--	--------	-----	----	------------	------	-----	------	----	------	-----	-----	----------	-----------	-----

[]	Items contained in this Information Disclosure Statement were first cited in any communication from a foreign patent office in a counterpart foreign application;
[1	In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
[]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
[]	This Statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed <i>per se</i> as a representation that such publication is prior art. Moreover, the Applicant understands that the Examiner will make an independent evaluation of the cited publications.
[~	[The Commissioner is hereby authorized to charge the fee pursuant to 37 CFR 1.17(P) in the amount of \$180.00, or further fees which may be due, to Deposit Account 50-1133.
[~	/]	None

SIGNATURE

Date: June 24, 2009

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Kristin A. Connarn, Reg. No.: 57,025

McDermott Will & Emery LLP

28 State Street Boston, MA 02108 Tel. (617) 535-4453 Fax (617) 535-3800 BST99 1622784-1 079259 0237